Sustained immune tolerance induction in enzyme replacement therapy–treated CRIM-negative patients with infantile Pompe disease

BACKGROUND. Cross-reactive immunological material–negative (CRIM-negative) infantile Pompe disease (IPD) patients develop an immune response against enzyme replacement therapy (ERT) with alglucosidase alfa that nullifies ERT efficacy. Prophylactic immune tolerance induction (ITI) with rituximab, met...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :JCI Insight
Главные авторы: Kazi, Zoheb B., Desai, Ankit K., Berrier, Kathryn L., Troxler, R. Bradley, Wang, Raymond Y., Abdul-Rahman, Omar A., Tanpaiboon, Pranoot, Mendelsohn, Nancy J., Herskovitz, Eli, Kronn, David, Inbar-Feigenberg, Michal, Ward-Melver, Catherine, Polan, Michelle, Gupta, Punita, Rosenberg, Amy S., Kishnani, Priya S.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Clinical Investigation 2017
Предметы:
Clinical Medicine
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5621909/
https://ncbi.nlm.nih.gov/pubmed/28814660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.94328
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы